Inactief instrument

Andere talen Dynavax Technologies Corporation Nasdaq

Aandelen

US2681581029

slotkoers Nasdaq Andere beurzen
- ^USD	-

14/05	Dynavax Technologies door Amerikaanse FDA geïnformeerd dat aanvraag voor vier doses hepatitis B-vaccin onvoldoende gegevens bevat	MT
14/05	US FDA weigert uitbreiding gebruik hepatitis B-vaccin van Dynavax goed te keuren	RE

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Dynavax Technologies Notified by US FDA That Application for Four-Dose Course of Hepatitis B Vaccine Lacks Sufficient Data	14/05
Dynavax Application for Hepatitis B Treatment Ruled Insufficient by FDA	14/05
US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine	14/05
Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.	14/05
Dynavax Technologies Corporation Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S	14/05
Dynavax Technologies: Q1 Earnings Snapshot	08/05
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Posts Q1 Revenue $50.8M, vs. Street Est of $55M	08/05
Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates	08/05
Dynavax Technologies Corporation Reaffirms Financial Guidance for the Full Year 2024	08/05
Dynavax Technologies Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Dynavax Technologies : Additional proxy soliciting material – supplement	30/04
Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024	24/04
Dynavax Technologies Corporation Announces Chief Financial Officer Changes	01/04
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference	28/02
Dynavax Technologies Reports Breakeven Q4 Earnings, Lower Revenue	23/02
Dynavax Technologies Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Reports Q4 Revenue $55.6M, vs. Street Est of $52.7M	22/02
Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2024	22/02
Dynavax Technologies Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance	22/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Dynavax Technologies Corporation Nasdaq

Aandelen

US2681581029

Andere talen

Filters